• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, November 16, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Review Evaluates Artificial Intelligence Applications in Cancer Stem Cell Immunotherapy

by
November 16, 2026
in Cancer
Reading Time: 7 mins read
0
Review Evaluates Artificial Intelligence Applications in Cancer Stem Cell Immunotherapy

Review Evaluates Artificial Intelligence Applications in Cancer Stem Cell Immunotherapy

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A comprehensive scientific review published in the Journal of the Egyptian National Cancer Institute critically evaluates the biological mechanisms of therapeutic resistance in cancer stem cells and outlines the translational maturity of artificial intelligence approaches designed to guide chimeric antigen receptor cellular immunotherapies. Authored by Visula Abeysuriya, Sachintha N. Alwis, and Vasitha Abeysuriya, the study examines the biological interplay among persistent cancer stem cell populations, engineered immune effector cells, and the surrounding immunosuppressive tumor microenvironment. While chimeric antigen receptor, or CAR, based cellular immunotherapies have transformed the clinical management of multiple hematological malignancies, achieving long-term eradication of cancer stem cells in solid tumors remains a formidable oncological challenge. Cancer stem cells possess intrinsic self-renewal capabilities, remarkable phenotypic plasticity, dynamic immune evasion strategies, and an ability to survive severe therapeutic stress, driving tumor recurrence, metastasis, and disease progression across diverse cancers. Computational methodologies and artificial intelligence platforms have emerged to process complex multi-omics data for antigen discovery, construct optimization, and patient stratification, yet the authors emphasize that current evidence supporting these computational tools ranges predominantly from theoretical models to retrospective clinical associations rather than prospective clinical trials.

Understanding cancer stem cell biology requires moving beyond the historical assumption that stemness represents a rigid, permanently fixed cellular phenotype within a malignant tissue. The review details how cancer stem cells demonstrate extensive phenotypic plasticity and dynamic state transitions, enabling non-stem differentiated tumor cells to reacquire stem-like capabilities under selective therapeutic pressure. These adaptive cellular transformations are mediated through developmental and survival signaling pathways, notably including Wnt/beta-catenin, Notch, Hedgehog, PI3K/AKT/mTOR, and Hippo cascades. Transcriptional and epigenetic reprogramming further permits neoplastic cells to modulate surface antigen density and switch functional phenotypes during the course of disease progression and immune-mediated therapy. Consequently, therapeutic interventions directed against static markers often fail because selective cytotoxic pressure merely filters the cellular population, prompting the enrichment of treatment-resistant stem-like variants. This dynamic behavior highlights an essential conceptual distinction between static surface biomarkers and evolving stemness states, illustrating why stable therapeutic targets have historically proven exceptionally difficult to define, validate, and permanently eliminate in heterogeneous clinical tumors.

Chimeric antigen receptor T cells currently represent the most clinically established cellular immunotherapy platform, engineered to achieve targeted tumor cytolysis through human leukocyte antigen or major histocompatibility complex independent recognition of cell-surface antigens. This major histocompatibility complex independent mechanism provides an essential therapeutic advantage, given that malignant cells frequently downregulate human leukocyte antigen class I presentation to escape conventional cytotoxic T-cell surveillance. Researchers have targeted numerous cancer stem cell associated surface antigens using CAR-T cells, including CD133, EpCAM, CD44, CD44v6, CD123, HER2, CSPG4, and variant EGFR molecules like EGFRvIII. Nevertheless, single-antigen CAR targeting is consistently compromised by antigen heterogeneity, post-treatment antigen loss, and lineage plasticity, which permit antigen-low or antigen-negative tumor subpopulations to survive and regenerate the malignant mass. In response, advanced construct engineering has yielded dual-targeting, tandem CAR, and logic-gated receptor circuits designed to broaden immune recognition and prevent antigen escape. However, the authors caution that broadening targeting breadth simultaneously increases engineering complexity and does not fully eliminate the critical safety threat of on-target, off-tumor toxicities.

Beyond conventional alpha-beta CAR-T lymphocytes, alternative cellular platforms have been engineered to address specific biological and clinical shortcomings, though their translational maturity varies substantially across the experimental spectrum. Chimeric antigen receptor natural killer cells integrate CAR-guided targeting with innate cytotoxic mechanisms, presenting distinct advantages for allogeneic, off-the-shelf therapeutic manufacturing because of their substantially reduced propensity to induce graft-versus-host disease compared to allogeneic T cells. CAR-NK platforms also exhibit a reduced risk of inciting life-threatening cytokine release syndrome and neurotoxicity in treated recipients. However, their therapeutic durability is severely constrained by limited in vivo cellular persistence, prompting investigators to explore genetic modifications such as interleukin-15 expression and cytokine-inducible SH2-containing protein gene disruption to enhance NK cell survival and metabolic endurance. Simultaneously, chimeric antigen receptor macrophages have emerged as an innovative cellular modality tailored for solid tumors, leveraging their intrinsic capacity to actively infiltrate dense tumor stroma, phagocytose target cells, remodel the local extracellular matrix, and present tumor antigens to endogenous lymphocytes, although CAR-M approaches currently lack the extensive clinical validation established by CAR-T modalities.

Other emerging engineered cellular platforms discussed in the review encompass gamma-delta CAR-T cells, chimeric antigen receptor invariant natural killer T cells, and CAR-engineered neutrophils, each operating through specialized biological mechanisms. Gamma-delta CAR-T cells unite engineered target recognition with intrinsic non-major histocompatibility complex restricted surveillance of cellular stress-associated signals, though their clinical translation is hindered by manufacturing hurdles, variable cellular persistence, and subset heterogeneity. Preclinical investigations have highlighted allogeneic, hematopoietic stem and progenitor cell derived CAR-iNKT platforms directed against diverse targets across ovarian carcinoma, CD70-positive renal cell carcinoma, mesothelin-positive triple-negative breast cancer, and EGFRvIII-positive glioblastoma. These invariant NKT cells utilize invariant T-cell receptors recognizing CD1d-presented lipid antigens to eliminate immunosuppressive CD1d-expressing cells in the tumor stroma alongside CAR-mediated cytotoxicity, providing a scalable, off-the-shelf option with low alloreactivity risk. Meanwhile, CAR-engineered neutrophils are primarily investigated at the preclinical stage to exploit their natural capacity for rapid infiltration into acutely inflamed tumor niches, functioning as targeted trafficking vehicles rather than validated platforms for cancer stem cell eradication.

Resistance to CAR-based cellular therapies is shaped not only by target dynamics but also by cell-intrinsic dysfunction and progressive immune exhaustion occurring within the engineered therapeutic cells themselves. Sustained exposure to tumor antigens, combined with chronic inhibitory signaling and metabolic deprivation, induces a progressive decline in immune cell proliferation, cytokine secretion, and cytotoxic capacity. The authors stress that elevated surface expression of inhibitory checkpoint molecules, such as programmed cell death protein 1, must not be conflated with irreversible, terminal T-cell exhaustion; checkpoint upregulation can reflect transient functional activation, whereas genuine exhaustion encompasses extensive epigenetic, transcriptional, and mitochondrial reprogramming. Engineering tactics including checkpoint blockade, checkpoint-resistant CAR architectures, and strategies that bolster mitochondrial fitness can mitigate functional exhaustion, but they do not universally eliminate cellular dysfunction in hostile tumor niches. Similarly, cancer stem cells frequently upregulate checkpoint molecules such as PD-L1 and the innate phagocytic checkpoint CD47 to evade immune destruction, demonstrating that effective therapeutic design requires balancing checkpoint disruption against normal tissue safety and hematological tolerability.

The immunosuppressive tumor microenvironment establishes a profound physical, cellular, and biochemical barrier that systematically restricts CAR-cell trafficking, extravasation, proliferation, and anti-tumor effector functions. Rather than residing as passive bystanders within the stroma, cancer stem cells actively orchestrate and reinforce this protective local niche by releasing bioactive cytokines, chemokines, and extracellular vesicles. Cancer stem cell derived signaling molecules, including interleukin-6, interleukin-10, transforming growth factor-beta, CCL2, CCL5, vascular endothelial growth factor, and granulocyte-macrophage colony-stimulating factor, actively recruit and polarize immunosuppressive myeloid-derived suppressor cells, tumor-associated macrophages, and regulatory T lymphocytes. Concurrently, cancer-associated fibroblasts remodel the extracellular matrix, producing dense collagen deposition and increased interstitial tissue stiffness that physically exclude infused CAR effector cells from penetrating the malignant parenchyma. The bidirectional crosstalk between cancer stem cells and stromal elements creates an evolving ecosystem where therapeutic cellular pressure inevitably reshapes microenvironmental composition, selecting for cellular phenotypes that resist subsequent immune attack.

Metabolic derangements and localized hypoxic stress within the solid tumor microenvironment form an additional interconnected pillar of therapeutic resistance, directly suppressing infused effector cell metabolism while supporting stemness maintenance. Accelerated tumor glycolysis and aberrant cellular respiration generate extensive lactic acid accumulation, lowering extracellular pH to levels that suppress T-cell and natural killer cell cytotoxic functions, cytokine generation, and proliferative expansion. Hypoxic microenvironments downregulate effector CAR-T viability and impair expansion while activating hypoxia-inducible transcriptional programs within cancer stem cells that reinforce undifferentiated phenotypes and stemness preservation. Alterations in fatty-acid oxidation and lipid storage pathways similarly equip cancer stem cells with heightened resistance against immune-mediated apoptosis, simultaneously creating nutrient-depleted conditions that starve engineered immune cells of vital metabolic substrates. Preclinical research exploring metabolic reprogramming, such as engineering hypoxia-adaptive CAR constructs or enzymatically degrading accumulated intratumoral lactate, shows promise in laboratory models, but these metabolic interventions have not yet proven capable of securing durable, long-term cancer stem cell eradication in clinical patient populations.

Artificial intelligence and machine-learning algorithms offer powerful computational frameworks capable of integrating high-dimensional genomic, transcriptomic, single-cell, spatial transcriptomic, proteomic, and clinical datasets to guide precision immunogenetics. In this context, precision immunogenetics denotes the systematic computational synthesis of molecular and clinical parameters to design individualized cellular immunotherapies. Machine-learning models can prioritize candidate cancer stem cell antigens by mining multi-omics libraries and spatial profiling maps to identify signature expression profiles that distinguish stem-like states from differentiated tumor bulk. Furthermore, artificial intelligence structural algorithms assist in predicting receptor-antigen binding affinities, hinge configurations, and intracellular signaling kinetics during CAR construct design. Computational models also analyze multi-modal patient parameters to forecast therapeutic toxicities, stratify responsive cohorts, and evaluate tumor-to-normal tissue antigen expression ratios to delineate safe therapeutic windows. Theoretical digital-twin paradigms have even been proposed to simulate patient-specific treatment responses over time; however, these mathematical simulations remain largely conceptual because continuous stem cell plasticity, parameter uncertainty, and spatial tumor heterogeneity prevent accurate, prospective patient-level therapeutic forecasting.

The review concludes by outlining essential translational priorities and defining the evidence maturity across artificial intelligence enabled immunotherapies, urging the field to distinguish computational predictions from demonstrated clinical efficacy. The authors emphasize a rigorous, stepwise developmental trajectory advancing sequentially from biological rationale to computational discovery, experimental validation, preclinical animal testing, and ultimately prospective clinical trials. Current computational platforms encounter significant technical bottlenecks, including the profound scarcity of well-annotated, standardized cancer stem cell clinical datasets, batch effects across sequencing platforms, sampling biases, and model data leakage that artificially inflates algorithmic accuracy. Because computational biomarker identification does not establish that targeted ablation will yield clinical tumor eradication, artificial intelligence must currently be regarded as an exploratory discovery and decision-support technology rather than an independently validated therapeutic intervention. Advancing the field demands international multi-center data standardization, longitudinal single-cell profiling of treated tumors, explainable algorithmic architectures with defined regulatory accountability, and rigorous prospective clinical trials to determine whether computationally guided CAR designs improve measurable patient survival.

Subject of Research: Artificial intelligence applications and chimeric antigen receptor platforms targeting cancer stem cells

Article Title: Artificial intelligence-driven precision immunogenetics for cancer stem cell-targeted CAR immunotherapy

Article References: Abeysuriya, V., Alwis, S. N., & Abeysuriya, V. (2026). Artificial intelligence-driven precision immunogenetics for cancer stem cell-targeted CAR immunotherapy. Journal of the Egyptian National Cancer Institute, 38(1), Article 84. https://doi.org/10.1186/s43046-026-00422-2

Image Credits: AI Generated

DOI: 10.1186/s43046-026-00422-2

Keywords: Cancer Stem Cells, Chimeric Antigen Receptor, CAR-T Cell Therapy, CAR-NK Cells, CAR-Macrophages, CAR-iNKT Cells, Artificial Intelligence, Precision Immunogenetics, Tumor Microenvironment, Antigen Heterogeneity, T-Cell Exhaustion, Cancer-Associated Fibroblasts, Immune Checkpoints, Metabolic Resistance, Multi-Omics Integration, Digital Twins, Preclinical Validation, Prospective Clinical Trials

News Source: Nathaniel Bowman. (November 16, 2026). Review Evaluates Artificial Intelligence Applications in Cancer Stem Cell Immunotherapy. Scienmag.

Tags: antigen heterogeneityArtificial Intelligencecancer stem cellsCancer-associated fibroblastsCAR macrophagesCAR-iNKT CellsCAR-NK cellsCAR-T cell therapychimeric antigen receptordigital twinsimmune checkpointsMetabolic ResistanceMulti-omics integrationPrecision Immunogeneticspreclinical validationProspective Clinical TrialsT cell exhaustiontumor microenvironment
Share12Tweet7Share2ShareShareShare1

Related Posts

Ultrasound Radiomics Distinguishes Rare Phyllodes Breast Tumors From Cancer and Fibroadenomas

Ultrasound Radiomics Distinguishes Rare Phyllodes Breast Tumors From Cancer and Fibroadenomas

November 16, 2026
Multimodal Regimen Enables Complete Remission in Rare Advanced Pulmonary NUT Carcinoma

Multimodal Regimen Enables Complete Remission in Rare Advanced Pulmonary NUT Carcinoma

November 16, 2026

HDAC1 Epigenetically Silences CDX2 to Promote Colorectal Cancer Cell Migration

November 16, 2026

US Esophageal Cancer Mortality Rates Fell While Overall Deaths Rose Through 2023

November 16, 2026

POPULAR NEWS

  • Maintenance BCG Reduces Bladder Cancer Progression When Patients Overcome Treatment Barriers

    Maintenance BCG Reduces Bladder Cancer Progression When Patients Overcome Treatment Barriers

    29 shares
    Share 12 Tweet 7
  • High-Avidity BCMA CAR T-Cell Therapy Shows High Efficacy in AL Amyloidosis

    29 shares
    Share 12 Tweet 7
  • Zero Mass Limit in Karch-Randall Gravity Yields Decoupled Massive Vector Theory

    29 shares
    Share 12 Tweet 7
  • Kenyan Smallholder Farmers Classify Diverse Pasture Species for Sustainable Dairy Production

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Resting-state Brain Age Links Neurodevelopmental Burden to Schizophrenia Severity

Low Preoperative Nutritional Index Predicts ICU Admission After Orthopedic Surgery

Social Disconnection Mediates Genetic Vulnerability to Suicidal Ideation and Depression

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 87 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.